Market Newsdesk

Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Executive Director, Biotech Equity Research for Oppenheimer & Co. at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 9:55 a.m. ET.

A live webcast of the conversation will be available on the Investors & Media page of the company’s website. The event will remain archived on the website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005214/en/

Corporate Contact:

Joshua Reed

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

[email protected]

Investor & Media Contact:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Optical Health

MEDIA:

Logo

The RMR Group Appoints Andrew Fay Senior Vice President

$32 Billion Alternative Asset Manager Enhances Capability to Source Private Capital for Investments in Core Real Estate

Financial Industry Veteran Brings 30 Years of Experience to RMR

NEWTON, Mass.–(BUSINESS WIRE)–The RMR Group Inc. (Nasdaq: RMR) today announced the appointment of Andrew Fay as Senior Vice President. In this new role, Mr. Fay will be responsible for establishing and developing a capital markets team that will focus on sourcing capital from private investment partners including ultra-high net worth investors, family offices, targeted registered investment advisors, foundations and endowments.

Adam Portnoy, President & Chief Executive Officer, made the following statement:

“We welcome Andy to RMR’s senior leadership team and look forward to utilizing his multi-decade experience in the capital markets and wealth management industries and his ability to build relationships with ultra-high net worth investors, family offices and institutions. We believe that RMR’s strong historical track record and expertise in managing a diverse, nationwide portfolio of core real estate assets will appeal to new audiences and will complement the traction we have already established with investments from sovereign wealth funds.”

The creation of this new role builds on RMR’s effort to expand its capital sources into private markets and so far has resulted in nearly $1 billion of new investment, primarily from sovereign wealth funds. This capital includes investments in, most notably, the $680 million joint venture RMR client Industrial Logistics Properties Trust (Nasdaq: ILPT) entered into for 12 mainland U.S. industrial assets.

Mr. Fay has more than 30 years of experience in financial services and expertise in both the institutional and private client marketplace. He most recently served as Head of Family Office Services for Fidelity Investments, where he played a central role in creating the company’s first ultra-high net worth and family office business. Previously, he held roles at Bank Boston and FleetBoston Securities Corp. as well as Manufacturers Hanover Trust. Mr. Fay is an advisory board member of the UNWH Institute. He earned his Bachelor’s degree in Government and French with a minor in Economics from Bowdoin College and is a certified investment management analyst.

About The RMR Group

The RMR Group Inc. (Nasdaq: RMR) is a holding company and substantially all of its business is conducted by its majority owned subsidiary, The RMR Group LLC, or RMR. RMR is a leading U.S. alternative asset management company, unique for its focus on commercial real estate (CRE) and related businesses. RMR’s vertical integration is supported by its more than 600 real estate professionals in over 30 offices nationwide who manage over $32 billion in assets under management and leverage 35 years of institutional experience in buying, selling, financing and operating CRE. RMR benefits from a scalable platform, a deep and experienced management team and a diversity of direct real estate strategies across its clients. RMR is headquartered in Newton, MA and was founded in 1986. For more information, please visit www.rmrgroup.com.

WARNING REGARDING FORWARD LOOKING STATEMENTS

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon RMR’s present beliefs and expectations, but these statements and the implications of these statements are not guaranteed to occur and may not occur for various reasons, some of which are beyond RMR’s control. For example:

• The appointment of Mr. Fay and the enumeration of his qualifications may imply that RMR’s business and operations will improve as a result of his appointment. However, RMR’s business and operations are subject to various risks, many of which are beyond its control. As a result, RMR’s business and operations may not improve despite the appointment of Mr. Fay.
• Mr. Portnoy states that RMR looks forward to utilizing Mr. Fay’s experience in the capital markets and wealth management industries and his ability to build relationships with ultra-high net worth investors, family offices and institutions and believes that RMR’s strong historical track record and expertise in managing a diverse, nationwide portfolio of core real estate assets will appeal to new audiences. There can be no assurance, however, that the appointment of Mr. Fay will enhance RMR’s ability to source private capital or provide any benefit to RMR’s shareholders or client companies.

For these reasons, among others, investors are cautioned not to place undue reliance upon any forward looking statements in this press release. Except as required by law, RMR does not intend to update or change any forward looking statements as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005182/en/

Christopher Ranjitkar

Senior Director, Marketing & Corporate Communications

(617) 219-1473

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo

Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

Initial Data from the Phase 2 Trial Expected in 2022

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the SELECT-AML-1 clinical trial of tamibarotene, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine. The randomized Phase 2 trial is enrolling RARA-positive newly diagnosed unfit patients with acute myeloid leukemia (AML).

“Despite recent advances, one third of newly diagnosed unfit AML patients still don’t respond to front-line treatment and many more relapse,” said Eytan M. Stein, M.D., Assistant Professor of Medicine and Director of the Program for Drug Development in Leukemia at Memorial Sloan Kettering Cancer Center. “These patients need new therapies that can deliver durable remissions with minimal or manageable toxicities. I am encouraged by tamibarotene’s distinct safety profile, as well as the compelling clinical and translational data that has emerged, suggesting it may benefit patients in the greatest need of new treatment options. I look forward to further exploring its potential in this clinical trial as part of a triplet regimen with venetoclax and azacitidine.”

Tamibarotene has demonstrated promising results in combination with azacitidine in RARA-positive newly diagnosed AML patients who are not suitable candidates for standard chemotherapy. At the 62^nd American Society of Hematology (ASH) Annual Meeting in December 2020, Syros presented data from a Phase 2 clinical trial, demonstrating a 67% overall response rate and a 61% composite complete response (CR/CRi) rate. The data also showed that tamibarotene in combination with azacitidine was generally well-tolerated, with no evidence of increased myelosuppression compared to single-agent azacitidine.

Also at ASH, Syros presented translational data demonstrating that most RARA-positive newly diagnosed unfit AML patients in the Phase 2 trial of tamibarotene had a monocytic disease phenotype associated with resistance to venetoclax, which, in combination with azacitidine, is the standard of care for newly diagnosed unfit patients. These data suggest that the RARA biomarker selects for patients who are more likely to benefit from tamibarotene and who may be less likely to benefit from venetoclax.

“AML is a complex, heterogenous disease, and many patients may present upfront with both monocytic and non-monocytic leukemia cells,” said David A. Roth, M.D., Chief Medical Officer at Syros. “By employing a triplet strategy that combines tamibarotene with venetoclax and azacitidine, we believe we can simultaneously target both cell types, reducing the emergence of resistant disease and increasing the likelihood of deeper and more durable responses. We are excited to be actively enrolling patients in this study, as we advance our portfolio of targeted hematology therapies with the aim of setting new standards of care for people with acute leukemias and myelodysplastic syndrome.”

The SELECT-AML-1 trial is designed with a single-arm safety lead-in, followed by the randomized portion of the trial, which will evaluate the safety and efficacy of tamibarotene in combination with venetoclax and azacitidine compared to venetoclax and azacitidine in approximately 80 patients randomized 1:1. The trial will also evaluate the triplet regimen as a salvage strategy in patients in the control arm who do not respond to venetoclax and azacitidine. The primary endpoint of the trial will be composite CR rate.

Syros is also evaluating tamibarotene in combination with azacitidine in the SELECT-MDS-1 Phase 3 clinical trial in RARA-positive patients with newly diagnosed higher-risk myelodysplastic syndrome.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding Syros’s clinical development plans, including with respect to tamibarotene, the timing of anticipated data readouts from the SELECT-AML-1 trial, and the ability of tamibarotene to have a benefit for patients. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including Syros’ ability to: advance the development of tamibarotene under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of tamibarotene; sustain the response rates and durability of response seen to date with tamibarotene; successfully develop a companion diagnostic test to identify patients with the RARA biomarker; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption “Risk Factors” in Syros’ Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, each of which is on file with the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the future. In addition, the extent to which the COVID-19 pandemic continues to impact Syros’ workforce and its clinical trial operations activities, and the operations of the third parties on which Syros relies, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the pandemic, additional or modified government actions, and the actions that may be required to contain the virus or treat its impact. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syros expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005159/en/

Media Contact

Naomi Aoki

Syros Pharmaceuticals

617-283-4298

[email protected]

Investor Contact

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Genetics Pharmaceutical Clinical Trials

MEDIA:

Logo

Ontrak Names Dr. Robert Accordino Chief Medical Officer

Mental Healthcare Leader and Harvard Medical School Faculty Member Joins Ontrak

SANTA MONICA, Calif.–(BUSINESS WIRE)–
Ontrak, Inc (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Dr. Robert Accordino as Ontrak’s Chief Medical Officer, effective September 27, 2021. Dr. Accordino joins Ontrak from Quartet Health where he served as the company’s most senior clinician and Chief Mental Health Officer. He practices psychiatry and is on the faculty of Harvard Medical School and Massachusetts General Hospital. Dr. Accordino will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year.

“Dr. Accordino’s reputation in the healthcare industry speaks volumes about his talent and impact,” said Jonathan Mayhew, Ontrak CEO. “He is a sought after thought leader, having given over 80 conference, grand rounds and seminar presentations and engaged in clinical research that has resulted in over 40 peer-reviewed publications, book chapters and articles. Last year, he was named one of the Top 25 Emerging Leaders by Modern Healthcare. Dr. Accordino’s appointment is the third in a series of new executive leadership appointments that further strengthen our management team. As Chief Medical Officer of Ontrak, Dr. Accordino will be responsible for all of our clinical operations, provider network, and care community training. He will also guide the clinical development of our new care pathways, products, and services, leveraging our landmark Treatment Effect Study for the benefit of customers and members.”

Dr. Accordino stated, “Ontrak has a demonstrated ability to engage those who others have not been able to reach. I’m deeply impressed by the company’s commitment to whole person care, addressing physical, mental and social health needs. I am deeply humbled and tremendously excited to join the Ontrak team and work alongside them to advance the clinical experiences and outcomes for all of the members whom Ontrak serves.”

As Chief Mental Health Officer at Quartet Health, Dr. Accordino led and executed the company’s clinical strategy. During his tenure, Quartet’s geographic footprint and digitally-enabled care increased significantly. Prior to this, Dr. Accordino was Chief of Psychiatry and Behavioral Health at CareMore, an innovative health plan and care delivery system with over $1.2B in revenue and over 100,000 members in eight states. From 2016-2017, Dr. Accordino served as the White House Fellow to the Secretary of Defense and chaired the Secretary of the Army Symposium on Suicide Prevention and Social Media.

As a medical student, Dr. Accordino founded the nonprofit organization, Music for Autism, and continues to support its work as Chair of their Board of Directors. Additionally, he serves on the Board of Directors of Hope in a Box. Dr. Accordino holds a Bachelor of Arts in Psychology from Princeton University, a Master of Science in Experimental Psychology from Oxford University, and a Doctor of Medicine from Mount Sinai School of Medicine.

About Ontrak, Inc.

Ontrak, Inc. (f/k/a Catasys, Inc.) is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.

Learn more at www.ontrakhealth.com

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in regulations or issuance of new regulations or interpretations, limited operating history, our inability to execute our business plan, increase our revenue and achieve profitability, lower than anticipated eligible members under our contracts, our inability to recognize revenue, lack of outcomes and statistically significant formal research studies, difficulty enrolling new members and maintaining existing members in our programs, the risk that treatment programs might not be effective, difficulty in developing, risks of retaining key personnel and customers, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the health care industry, the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, our ability to raise additional capital when needed and our liquidity. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plan,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. Forward looking statements may include statements regarding our proprietary IP and technological innovation allowing us to identify, engage, and create lasting behavior change in the lives of those with unaddressed behavioral health conditions and chronic disease. For a further list and description of the risks and uncertainties we face, please refer to our most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005123/en/

Investors:

Caroline Paul

Gilmartin Group

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Mental Health Telecommunications Software Practice Management Managed Care Health General Health Data Management

MEDIA:

Logo

Terminix Releases Top 50 Bed Bug Cities as College Students Return to Campus

Los Angeles itches its way to the top, making the possibility of a bed bug as a roommate very real for college students in the City of Angels

MEMPHIS, Tenn.–(BUSINESS WIRE)–
Just in time for back-to-school, Terminix Global Holdings, Inc. (NYSE: TMX), a leading provider of essential pest, termite, mosquito and bed bug control services for residential and commercial customers, released a list of the top 50 most bed-bug infested cities in America.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005092/en/

Students have arrived on college campuses nationwide, and joining them could be some annoying and uninvited roommates taking up residence in dormitories. Bed bugs spread easily by hitching rides on luggage, backpacks and clothing, and can crawl through cracks in the walls, making common spaces of dorm living extremely vulnerable to infestations.

“Bed bugs go where people go, so they can be virtually anywhere,” says Rick Cooper, senior director of bed bug services at Terminix. “Bed bugs move from infested structures – whether that be hotels, airports, schools or college campuses. They can tag along on someone’s clothes or backpack. Bed bugs are an extremely difficult pest to control, but Terminix has the expertise, proper tools and techniques to assess and address the problem correctly.”

Where Are Bed Bugs Most Common?

The top five cities on this year’s most infested list include Los Angeles claiming the top spot, followed by Cleveland, Philadelphia, Detroit and New York City. Thirteen states had more than one city on the list, including Alabama, Arkansas, California, Florida, Indiana, Kentucky, Michigan, Missouri, Ohio, Oklahoma, Pennsylvania, Tennessee and Texas.

Terminix based its rankings on the number of requests received from each city in 2021*. The top 50 cities for bed bug infestations in the United States are:

1. Los Angeles, Calif.	18. Tampa, Fla.	35. South Bend, Ind.
2. Cleveland, Ohio	19. Louisville, Ky.	36. Miami, Fla.
3. Philadelphia, Pa.	20. Phoenix, Ariz.	37. Flint, Mich.
4. Detroit, Mich.	21. Dayton, Ohio	38. Shreveport, La.
5. New York, N.Y.	22. Denver, Colo.	39. Kansas City, Mo.
6. Chicago, Ill.	23. Oklahoma City, Okla.	40. Ft. Smith, Ark.
7. Dallas, Texas	24. Nashville, Tenn.	41. Springfield, Mo.
8. Indianapolis, Ind.	25. Boston, Mass.	42. Mobile, Ala.
9. Cincinnati, Ohio	26. Lexington, Ky.	43. Seattle, Wash.
10. Atlanta, Ga.	27. Orlando, Fla.	44. Milwaukee, Wis.
11. Columbus, Ohio	28. Little Rock, Ark.	45. San Diego, Calif.
12. Houston, Texas	29. Baltimore, Md.	46. Fresno, Calif.
13. San Francisco, Calif.	30. Charleston, W.Va.	47. Tulsa, Okla.
14. St. Louis, Mo.	31. Paducah, Ky.	48. Las Vegas, Nev.
15. Washington, D.C.	32. Toledo, Ohio	49. Sacramento, Calif.
16. Pittsburgh, Pa.	33. Birmingham, Ala.	50. Dothan, Ala.
17. Memphis, Tenn.	34. Grand Rapids, Mich.

Signs of Bed Bugs and Where to Look

A few ways to identify the presence of bed bugs include small blood smears on your sheets, a musty odor, reddish-brown blood spots on your mattress, and bed bugs themselves. In dorm rooms, they tend to live in dressers, clothes, floorboards, couches and mattresses. When fully grown, bed bugs resemble the size, shape and color of an apple seed; however, students should also be on the lookout for recently hatched, cream-colored bed bugs (nymphs) hiding in their fitted sheets.

How to Protect Against Bed Bugs on Campus

Here are a few simple protective measures to help prevent the spread of bed bugs across campuses:

1. Add bed bug-proof encasements for your mattress, pillows and box spring to your back-to-school shopping list. Their protective casings will help prevent your bed from becoming a bed bug breeding ground.
2. Thoroughly search your new dorm room or apartment on move-in day. Take time to lift mattresses, move furniture and peek behind headboards for any signs of bed bugs, including discarded shells (molted exoskeletons); live or dead bugs at mattress seams or furniture joints; a sweet, musty odor; or small blood stains from previous bite victims.
3. Crack open your textbooks. Bed bugs have been known to travel from one place to the next via the “Second-Hand Textbook Express.”
4. Hot launder any borrowed or second-hand clothing (following labeled washing directions).
5. Resist the temptation to pick up discarded furniture. Although a free futon might be appealing, a lurking bed bug infestation is not.
6. Never leave backpacks or clothing on, under, or near your bed, chairs or upholstered furniture in your room or rooms you are visiting – it’s an easy way to unknowingly transfer hitchhiker bed bugs.
7. Don’t let your backpack come into contact with others — brief contact with an infested backpack can be an unwanted pest’s invitation to tag along.

For more information, visit Terminix.com or call 1-800-Terminix.

*This ranking was created by compiling bed bug-specific data from Terminix branches across the country. The rankings represent Metropolitan Statistical Areas (MSAs) with the most leads received between January 1, 2021, and August 20, 2021.

About Terminix

Terminix Global Holdings (NYSE: TMX) is a leading provider of residential and commercial pest control. The company provides pest management services and protection against termites, mosquitoes, rodents and other pests. Headquartered in Memphis, Tenn., with more than 11,400 teammates and 2.9 million customers in 24 countries and territories, the company visits more than 50,000 homes and businesses every day. To learn more about Terminix, visit Terminix.com or LinkedIn.com/company/terminix.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005092/en/

James Robinson | 901.597.7521 | [email protected]

Drew Blake | 901.201.7151 | [email protected]

KEYWORDS: United States North America Tennessee

INDUSTRY KEYWORDS: Construction & Property Other Retail Building Systems Home Goods Other Travel University Retail Education Residential Building & Real Estate Travel

MEDIA:

Logo

Photo

As college students are back on campus this school year, Terminix ranked the most bed bug infested cities in the country. Did your city make the list? (Graphic: Business Wire)

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Annual Global Investment Conference, which runs from September 13 – 15, 2021. The conference will be held in a virtual format.

A webcast of Dr. Toselli’s presentation will be available on the Investor Relations – Events section of the company website at https://investors.invivotherapeutics.com/events, beginning September 13, 2021 at 7:00 am ET. Dr. Toselli and company management will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005089/en/

Investors:

Bret Shapiro, Managing Partner

CORE IR

[email protected]

(516) 222-2560

Media

Gina Nugent

Ten Bridge Communications

[email protected]

617-460-3579

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Science Research Clinical Trials

MEDIA:

Logo

Tenax Therapeutics to Present at the H.C. Wainwright 23^rd Annual Global Investment Conference

MORRISVILLE, N.C.–(BUSINESS WIRE)–
Tenax Therapeutics, Inc. (Nasdaq: TENX),a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright 23^rd Annual Global Investment Conference being held September 13-15, 2021.

Webcast link to presentation: https://journey.ct.events/view/926bd710-4ba5-44f5-bfab-51a6170965c6

The pre-recorded presentation will be available for viewing on-demand beginning Monday, September 13 at 7:00 A.M. (EST). This presentation will also be available on the Investors section of Tenax Therapeutics’ website at tenaxthera.com.

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. Tenax is developing a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, and expects to conduct a single pivotal trial pursuant to the 505(b)(2) pathway for regulatory approval. The Company also owns North American rights to develop and commercialize levosimendan and has recently released detailed results from the Phase 2 HELP Study of levosimendan in Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting. For more information, visit www.tenaxthera.com.

About Imatinib

Imatinib is an antiproliferative agent developed to target the BCR-ABL tyrosine kinase in patients with chronic myeloid leukemia. The inhibitory effects of imatinib on PDGF receptors and c-KIT suggested that it may be efficacious in PAH. Imatinib reversed experimentally induced pulmonary hypertension and has pulmonary vasodilatory effects in animal models and proapoptotic effects on pulmonary artery smooth muscle cells from patients with idiopathic PAH. In a phase 3 clinical trial imatinib produced significant improvements in exercise capacity, but a high rate of dropouts attributed largely to gastric intolerance prevented regulatory approval.

About Levosimendan

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and not available in the United States. Tenax Therapeutics acquired North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to matters beyond the Company’s control that could lead to delays in the clinical study, new product introductions and customer acceptance of these new products; matters beyond the Company’s control that could impact the Company’s continued compliance with Nasdaq listing requirements; the impact of management changes on the Company’s business and unanticipated charges, costs and expenditures not currently contemplated that may occur as a result of management changes; and other risks and uncertainties as described in the Company’s filings with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on March 31, 2021 and its quarterly report on Form 10-Q filed on August 16, 2021, as well as its other filings with the SEC. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Statements in this press release regarding management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005083/en/

Investor Contact:

John Mullaly

Managing Director

LifeSci Advisors, LLC

C: 617-429-3548

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Cardiology

MEDIA:

Logo